Will Exelixis's novel approach pay off in the current economic climate?
Frankie Trull wants to sell your company to Congress.
How companies plan to make money (really) off of embryonic stem cells.
New organizations want to help you succeed in biotech - for free.
FDA scientists are increasingly unhappy, due to in-house pressures and public
criticism. How can the agency restore what it once was?
Immune Control CEO Stephen Roth is banking on a controversial hypothesis and is
fashioning ways to block a neurotransmitter to fight autoimmune disease.
The legislation is credited with building biotech and spawning hundreds of drugs for
rare diseases. So why do some analysts hesitate to call it a success?
AstraZeneca's Karen Gotting-Smith is using a newly-created position to tackle some
John Prakash was once denied a job because of the way he looked. Now he spends his
career talking about why diversity is crucial to drug development.
At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and